CN101390880A - Use of sea collagen peptides in preparing medicine or food for protecting kidney function, delaying chronic renal failure - Google Patents
Use of sea collagen peptides in preparing medicine or food for protecting kidney function, delaying chronic renal failure Download PDFInfo
- Publication number
- CN101390880A CN101390880A CNA2008102283917A CN200810228391A CN101390880A CN 101390880 A CN101390880 A CN 101390880A CN A2008102283917 A CNA2008102283917 A CN A2008102283917A CN 200810228391 A CN200810228391 A CN 200810228391A CN 101390880 A CN101390880 A CN 101390880A
- Authority
- CN
- China
- Prior art keywords
- food
- peptide
- marine
- collagen peptide
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a marine collagen peptide and the application thereof in the preparation of medicine, health food or food used for the protection of renal function and slowing the progress of chronic renal failure. Marine collagen peptide is a group of low-molecular weight oligopeptide mixture generated through the hydrolysis of fish skins of marine fish (salmon, chinook salmon, tilapia and the like). The molecular weight of 70%-80% of oligopeptide is distributed between 200-1000Da. The marine collagen peptide has the advantages of easy absorption, fast absorption, low viscosity, good water-solubility. The experiments prove that the marine collagen peptide can have the efficacy of slowing the adenine-induced chronic renal function impairment of rats.
Description
Technical field
The present invention relates to a kind of marine bioactivity oligopeptide and new purposes thereof, is the purposes of marine collagen in preparation protection renal function medicine, health food or food of extracting from marine fishes specifically.Belong to medicine, health care of food field.
Background technology
(chronic kidney diseases CKD) often because of the onset concealment has become the first stealthy killer who threatens human health, constitutes greatly harm to human survival quality and social development to chronic renal disease.The remarkable increase of CKD sickness rate may be relevant with following factors: the sickness rate of (1) hypertension and diabetes raises year by year, and hypertension and diabetes are the important pathogenesiss that cause CKD; (2) along with the raising of people's living standard, the sickness rate of acute nephritis significantly descends, but the sickness rate of chronic nephritis do not descend, even rising trend is arranged; (3) kidney there is the Toxicity of Kidney of the medicine and the chemicals of damaging action; (4) kidney damage of bringing of air pollution etc.
Although in decades, people have carried out useful discussion from all many-sides such as diet, medicine, genes to prevention and the treatment problem of CKD, and the prognosis of CKD does not still have substantial change.Up to now, we still can not control the sexual development that carries out of CKD fully, and it is end nephropathy (ESRD) stage in latter stage, i.e. chronic kidney hypofunction that considerable CKD patient makes progress the most at last.At present, for the treatment of chronic kidney hypofunction, mainly be artificial substituting (dialysis) or biological substitution treatment (renal transplantation).
The high incidence of CKD, high disability rate, high medical expense will bring very big financial burden and thought pressure to patient and family thereof and unit.Therefore, how delaying chronic nephropathy patient renal function speed of worsening has become medical science and social problem that scientist pays close attention to.
Recently, international nephropathy association and international kidney foundation alliance unite proposal, and the 2nd Thursday in annual March is decided to be " world's kidney day ", have fully shown national governments, medical worker and the broad masses attention to chronic kidney disease.First " world's kidney day " is March 9 in 2006, and the theme of first " world's kidney day " is exactly " earlier detection of chronic kidney disease and prevention ".Discover that the commitment at CKD carries out effective therapeutic intervention, effect is good more.And marine bioactivity peptide class is because low toxicity, characteristics such as efficient have demonstrated good prospects for application in delaying chronic kidney disease takes place.
Biologically active peptide is meant the peptide matters with special physiological function.The Bayliss of London University's medical college in 1902 and Startling have found a kind ofly can cause the active material of pancreatic secretion from the gastrointestinal of animal, are called secretin, and this is the human biological activity peptide matters of finding for the first time.After this, be accompanied by the develop rapidly of biochemistry and Protocols in Molecular Biology, the research of peptide has obtained breakthrough, has become the new focus of present research.
Peptide and protein all are the chemical compounds that aminoacid is connected to form with amido link, and the aminoacid degree of polymerization of peptide is little than polymerization degree of protein.In addition; biologically active peptide has demonstrated antioxidation, antibiotic, antitumor, protection cardiovascular, immunomodulating, the anti-ageing biological action of waiting for a long time; and these functions are that single amino acids and parent protein are irreplaceable; these bioactive peptide be can use and medicine, vaccine and health product etc. can be used as; at present, R and D biologically active peptide based food has become a focus in international health product industry.Chinese patent application 01126649.X discloses the albumen-10.34 that one peptide species-people contains L-lactic acid dehydrogenase activity site, the polynucleotide of this polypeptide of encoding and produce the effect that the method for this peptide species and this polypeptide are used for the treatment of multiple diseases such as, renal failure as the rhythm of the heart not normal, metabolic cataract, peripheral neuropathy, infection through the DNA recombinant technique.Chinese patent application number 01126663.5 discloses the albumen-8.8 of one peptide species-people's phosphoric acid transferring enzyme system phosphorylation site, the encode polynucleotide of this polypeptide and produce the method for this peptide species and the method that this polypeptide is used for the treatment of multiple disease through the DNA recombinant technique,, renal failure not normal, metabolic cataract, peripheral neuropathy, infection etc. as the rhythm of the heart.
In recent years, people turn one's attention to the ocean one after another, extract biologically active peptide from marine organisms.This be because: the ocean is the abundantest field of resource on the earth, since the ecological environment of marine organisms species than the terrestrial organism complexity many, it gives halobiontic some special chemical constitution is still undiscovered in the terrestrial life body, and this makes the ocean become the resource treasure-house of original new drug and functional health-care food.Since the seventies in 20th century, people have isolated the novel and special high activity of hundreds thousand of kinds of chemical constitutions, the bioactive substance of high-drug-effect from marine organisms, comprise peptide class, protein-based, polysaccharide, alkaloids, terpenoid, Macrocyclic polyester class etc.The peptide class is the hugest compounds of quantity in the marine bioactivity material, reaches tens thousand of kinds more than, and a lot of marine peptide classes have physiologically actives such as antioxidation, immunomodulating, resisting hypertension, antitumor, inhibition platelet aggregation.
The effect that delays to take place for the marine bioactivity peptide is at present studied also seldom; if reach renal function protecting, prevent CKD, delay the effect that renal failure makes progress, the patient that slows down enters end-stage renal failure speed by the exploitation health food; not only economy but also practicality will be brought very big prospect to the health-care industry of China.
Summary of the invention
The purpose of this invention is to provide a kind of low-molecular-weight marine collagen and the purposes in preparation protection renal function, delaying chronic kidney hypofunction process medicine or food thereof.
Marine collagen peptide product provided by the invention is the one group of low-molecular-weight oligo peptide that is produced through hydrolysis by the fish skin of marine fishes (salmon fish, Oncorhynchi, tilapia etc.).Peptide molecular weight is distributed as:＜130Da contains 16.48%, 130～500Da and contains 47.90%, 500～1000Da and contain 22.13%, 1000～2000Da and contain 10.63%, 2000～3000Da and contain 2.18%,〉3000Da contains 0.67%.Various amino acid contents are: aspartic acid 7.29%, glutamic acid 12.22%, serine 4.23%, histidine 1.61%, glycine 13.46%, threonine 2.53%, arginine 6.08%, alanine 6.59%, tyrosine 0.003%, cystine 1.21%, valine 2.94%, methionine 0.03%, phenylalanine 2.51%, isoleucine 2.57%, leucine 4.64%, lysine 5.66%, proline 6.71%, total amino acids 80.28%.In addition, also have easy absorption, absorb characteristics such as fast, low viscosity, good water solubility.
Wherein said medicine is powder, granule, capsule, tablet, pill.
Wherein said food is starch-based product, milk and milk products, bean product, baking goods.
Specific embodiments
The present invention is further illustrated below in conjunction with specific embodiments, and these examples should be understood that only to illustrate, but not limit the scope of the invention by any way.
Embodiment: marine collagen delays the effect of rat chronic renal dysfunction due to the adenine
32 of healthy cleaning level male SD rats, body weight 233.31 ± 6.26g is provided by Department Of Medicine, Peking University's Experimental Animal Center, and cleaning level Animal House is raised 25 ℃ of feeding environment temperature, humidity 60%RH.The rat adaptability was raised after 3 days, according to body weight animal was divided into A at random, totally four groups of B, C and D, every group of 8 rats.And four groups the serum inosine and the level of blood urea nitrogen adjusted, guarantee the initial serum inosine of animal between each group and the horizontal there was no significant difference of blood urea nitrogen.The A group is matched group; The B group is chronic kidney damage model group; The C group is MCPs 1.125g/kg/d intervention group; The D group is MCPs 2.25g/kg/d intervention group, and the MCPs dosage in two intervention group is equivalent to 25 times and 50 times of human body recommended intake respectively.The filling stomach gives the rat distilled water of matched group, and the rat adenine 100mg/kg that gives model group sets up the model of chronic kidney damage, and two intervention group give the MCPs of above-mentioned two concentration when giving adenine.The filling stomach time is identical, irritates stomach amount 1ml/100g body weight, once a day, and 12 weeks of continuous irrigation stomach.The 0th, 1,3,5,8,12 weeks in experiment are detected the level of respectively organizing rat blood serum creatinine, blood urea nitrogen, collect 24 hours urine amount of rat, calculate creatinine clearance rate.
When testing for the 5th week, the apparent in view rising of model group animal serum inosine and blood urea nitrogen and matched group, endogenous inosine clearance rate obviously descends, MCPs 2.25g/kg/d intervention group animal serum inosine and blood urea nitrogen raise than matched group, but the serum inosine of identical time point and blood urea nitrogen are lower than model group and endogenous inosine clearance rate is higher than model group, and difference has significance (p＜0.05).And MCPs 1.125g/kg/d intervention group animal serum inosine and blood urea nitrogen also have a declining tendency than model group, but difference does not have statistical significance (p〉0.05).
The result shows that preparation of the present invention has the function of protection renal function, delaying chronic kidney hypofunction process.
Table 1 preparation of the present invention is to the influence of rat blood serum creatinine level
* expression is compared P＜0.05 with matched group; ▲ expression is compared P＜0.05 with model group
Table 2 preparation of the present invention is to the influence of rat blood serum urea nitrogen levels
* expression is compared P＜0.05 with matched group; ▲ expression is compared P＜0.05 with model group
Table 3 preparation of the present invention is to the influence of rat creatinine clearance rate
* expression is compared P＜0.05 with matched group; ▲ expression is compared P＜0.05 with model group
Claims (4)
1, a kind of marine collagen peptide product is characterized in that: the one group of low-molecular-weight oligo peptide that is produced through hydrolysis by the fish skin of marine fishes (salmon fish, Oncorhynchi, tilapia etc.).Peptide molecular weight is distributed as:＜130Da contains 16.48%, 130～500Da and contains 47.90%, 500～1000Da and contain 22.13%, 1000～2000Da and contain 10.63%, 2000～3000Da and contain 2.18%,〉3000Da contains 0.67%.Various amino acid contents are: aspartic acid 7.29%, glutamic acid 12.22%, serine 4.23%, histidine 1.61%, glycine 13.46%, threonine 2.53%, arginine 6.08%, alanine 6.59%, tyrosine 0.003%, cystine 1.21%, valine 2.94%, methionine 0.03%, phenylalanine 2.51%, isoleucine 2.57%, leucine 4.64%, lysine 5.66%, proline 6.71%, total amino acids 80.28%.In addition, also have easy absorption, absorb characteristics such as fast, low viscosity, good water solubility.
2, the purposes of the described marine collagen peptide product of claim 1 in preparation protection renal function, delaying chronic kidney hypofunction process medicine, health food or food.
3, as claim 2, wherein said medicine is powder, granule, capsule, tablet, pill, oral liquid.
4, as claim 2, wherein said food is starch-based product, milk and milk products, bean product, baking goods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008102283917A CN101390880A (en) | 2008-10-30 | 2008-10-30 | Use of sea collagen peptides in preparing medicine or food for protecting kidney function, delaying chronic renal failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008102283917A CN101390880A (en) | 2008-10-30 | 2008-10-30 | Use of sea collagen peptides in preparing medicine or food for protecting kidney function, delaying chronic renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101390880A true CN101390880A (en) | 2009-03-25 |
Family
ID=40491519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008102283917A Pending CN101390880A (en) | 2008-10-30 | 2008-10-30 | Use of sea collagen peptides in preparing medicine or food for protecting kidney function, delaying chronic renal failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101390880A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104667254A (en) * | 2013-11-29 | 2015-06-03 | 中国科学院兰州化学物理研究所 | Fish oligopeptide effervescent tablet and preparation method thereof |
| CN113304243A (en) * | 2021-04-23 | 2021-08-27 | 南方医科大学南方医院 | Application of human hair extracted bioactive peptide in preparation of treatment drug for improving chronic kidney disease protein metabolism and drug |
-
2008
- 2008-10-30 CN CNA2008102283917A patent/CN101390880A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104667254A (en) * | 2013-11-29 | 2015-06-03 | 中国科学院兰州化学物理研究所 | Fish oligopeptide effervescent tablet and preparation method thereof |
| CN113304243A (en) * | 2021-04-23 | 2021-08-27 | 南方医科大学南方医院 | Application of human hair extracted bioactive peptide in preparation of treatment drug for improving chronic kidney disease protein metabolism and drug |
| CN113304243B (en) * | 2021-04-23 | 2023-07-04 | 南方医科大学南方医院 | Application of human hair extracted bioactive peptide in preparing medicine for improving chronic kidney disease protein metabolism and medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105324114B (en) | Astaxanthin anti-inflammatory synergistic combination | |
| CN104257583B (en) | Pearl enzymolysis solution and preparation method thereof | |
| CN101020719B (en) | Composite angelica polysaccharide and its preparation process and use | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| CN102153668A (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| CN105944103B (en) | A kind of natural hypoglycemic medicine of oral administered compound | |
| KR20160064966A (en) | Medical composition and applications thereof used for secondary chemotherapy drugs | |
| CN104531818A (en) | Preparation method of anti-tumor cuora trifasciata polypeptide | |
| CN101518645A (en) | Application of marine collagen peptide in preparing drugs, health care food or food for protecting renal function and delaying the process of chronic renal failure | |
| CN101301465A (en) | Fowl transfer factor nano liposomes and preparation thereof | |
| CN101390880A (en) | Use of sea collagen peptides in preparing medicine or food for protecting kidney function, delaying chronic renal failure | |
| CN101054414B (en) | Method of extracting and preparing deer DGF | |
| CN101890152B (en) | Application of Chinese yam glycoprotein in preparation of antihypoxic and antifatigue medicaments | |
| CN106749742B (en) | Polysaccharides in Cultured Cordyceps militaris, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN107056959A (en) | Jerusalem artichoke moderate resistance HSV 1, the composition of RSV, EV 71 and preparation | |
| CN103169946B (en) | Application of Safenour cyclopeptide in oral insulin medicine for treating diabetes | |
| CN1602200A (en) | Plant extract active as an immunostimulating agent | |
| CN101081865B (en) | Abstraction of pilose antler releasing somatomedin (DEER GHRF) and preparation method thereof | |
| CN100549025C (en) | Resultant seven peptides and the synthetic method of a kind of thymopeptide-5 and pidotimod | |
| CN103936845A (en) | Anti-microbial peptide from Chinese softshell turtle, as well as gene, preparation method and application thereof | |
| CN101491543A (en) | Use of sea collagen peptide in preparing medicine or food capable of improving senility memory function | |
| CN103012555A (en) | Preparation method for new polypeptide having tissue protection activity, and application of new polypeptide in treatment | |
| CN108185245A (en) | A kind of preparation method of ginseng dish's soy drink | |
| CN101167759B (en) | Mushroom fermentation dry powder preparation with anti-tumor activity and preparation method | |
| CN1267107C (en) | Extraction method of scorpion active protein liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090325 |